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Objective: To study whether locally administered recombinant i activated human coagulation factor VIIa (FFR-rFVIIa) 
would reduce the thrombus formation and improve patency in an experimental venous thrombosis model without inducing 
systemic changes in the coagulation. 
Design" Experimental double-dummy randomised study. 
Materials: In 20 healthy New Zealand White rabbits both jugular veins were exposed under general anaesthesia. 
Methods: The thrombi were induced in a 10 mm long jugular vein segment with a combination ofchemical destruction 
of the intima and a restriction of the bloodflow. Each segment was treated with either FFR-rFVIIa or placebo injected 
directly into the vein. 
Results: 1.5 mg topically applied FFR-rFVIIa significantly reduced the thrombus weight (p<O.O01). The 30 and the 
120 min patency tests were significantly improved (p<O.05 and p<O.O01, respectively). Plasma nalyses (APTT, dilute- 
TF time, FVII protein) were evaluated as baseline, 3 min after declamping and at sacrifice. No prolongation ofthe clotting 
times were seen. FFR-rFVIIa protein was detected in minute amounts (ng/ml); however, this was not enough to prolong 
the dilute-TF time. 
Conclusions: Local application of recombinant active-site inhibited human FVIIa reduced both thrombus weight and 
improved patency significantly inan experimental venous thrombosis model without affecting the systemic clotting times. 
Key Words: Inactivated FVIIa; FVIIa; TF; TF-FVII-dependent coagulation; Venous thrombosis; Patency. 
Introduction 
The procoagulant vessel wall transmembrane protein 
TF is not normally exposed to circulating blood. How- 
ever, in the atherosclerotic patient TF has been dem- 
onstrated within the plaque. 1 If the vessel wall is 
damaged or the plaque ruptures TF becomes exposed 
to the circulating blood. Factor VIIa, present in the 
circulating blood, binds to TF and the TF-FVIIa com- 
plex activates factor IX and X. Factor Xa (together with 
FVa, phospholipids and Ca 2+) activates prothrombin to 
thrombin. Additional FXa is generated via the tenase- 
complex (FIXa, FVIIIa, phospholipids and Ca2+). Ul- 
timately cross-linked fibrin is formed. The TF-de- 
pendent haemostasis i  controlled by tissue factor 
pathway inhibitor (TFPI). TFPI is an endogenous 
Kunitz type inhibitor, which inhibits the TF-FVIIa 
complex in an FXa dependent manner. The resulting 
* Please address all correspondence to: J. Holst, Dept. of Surgery, 
Helsingborg Hospital, S-251 87 Helsingborg, Sweden. 
quaternary TF-FVIIa:TFPI-FXa complex is devoid of 
enzymatic activity on FX and FIX. 2-4 Recently anti- 
thrombin and negatively charged glycosaminoglycans 
have also been recognised as playing a potential role 
as regulators of this crucial pathwayd The relative 
importance of TFPI versus antithrombin is still being 
discussed. B,6 
Since TF is the key initiator of the haemostasis, it is 
logical to target future therapeutic strategies towards 
the TF-FVIIa complex, especially since the inhibition 
of the end products of the coagulation cascade have 
clinically demonstrated a substantial risk of haem- 
orrhagic adverse vents. 7 To further minimize such a 
risk the potentially active antithrombotic substance 
may be delivered directly to the thrombogenic site. 
Such a delivery may require a lower dose and po- 
tentially prove more efficacious as compared to sys- 
temic delivery. A novel way to modulate the TF- 
dependent coagulation is to allow a recombinant act- 
ive-site inhibited human FVIIa (FFR-rFVIIa) to com- 
pete with endogenous FVIIa for the binding sites of 
1078-5884/98/060515+06 $12.00/0 © 1998 W.B. Saunders Company Ltd. 
516 J. Hoist et al. 
TF. FFR-rFVIIa binds to TF with high affinity and the 
resulting complex is devoid of enzymatic activity on 
FIX and FX and therefore would inhibit the activation 
of the coagulation cascade. 
FFR-rFVIIa has previously been evaluated in dif- 
ferent settings8 -15 (further details in the discussion), 
but not in an experimental venous thrombosis model. 
The purpose of this study was therefore to evaluate 
whether FFR-rFVIIa (1.5 mg), administered topically 
into a 10 mm long jugular vein segment, would reduce 
thrombus weight and improve patency without in- 
ducing changes in the systemic oagulation. 
Material and Methods 
Design 
The study was designed as a double-dummy ran- 
domised study in a total of 20 New Zealand White 
rabbits. Both jugular veins were used in all animals; 
one receiving active substance and the other one 
placebo (the vehicle of the active substance). Thus the 
animal served as its own control. The entire series of 
operations were performed by the same surgeon. 
Materials and animals 
Recombinant human FVIIa was purified from culture 
media of a transfected baby hamster kidney cell line 
as previously described) 6 The recombinant FVIIa 
was inactivated by the tri-peptide Phe-Phe-Arg- 
Chloromethyl ketone (FFRcmk, Bachem, Switzerland). 
The tri-peptide is covalently bound to the active-sites 
His-193 and Ser-344, which were thereby blocked. In 
a cell surface binding study (human carcinoma cell 
line, J82) FFR-rFVIIa had the same or superior binding 
affinity to TF compared to rFVIIa. 17 The FFR-rFVIIa 
solution was adjusted to a concentration of 1.5 mg/ 
ml and dissolved in buffer (10 mM Gly-Gly, 10 mM 
CaC12, 150 mM NaC1), was filtered under sterile con- 
ditions and stored in 1.0 ml aliquots at -80  °C. The 
buffer solution was used as the vehicle. 
New Zealand White rabbits of equal gender dis- 
tribution and with a mean weight of 2.3kg 
(S.D._+0.1kg) were purchased, handled and ac- 
climatised according to inhouse regulations of Bio- 
logical Services (Novo Nordisk, Denmark). The 
animals were kept there until one day prior to the 
experiment and thereafter at the operating facility until 
sacrifice. 
Sedation anaesthesia 
The animals were sedated with 5 mg diazepam intra- 
muscularly 15min prior to anaesthesia. Sodium 
pentobarbital (5mg/ml) was administrated intra- 
venously as a bolus and the anaesthesia was maintained 
with continuous infusion of sodium pentobarbital 
( ~ 2.5 mg/ml/h)  to securely abolish the corneal reflex. 
Prior to the surgical incision local anaesthesia (25 mg 
lidocain) was administrated on the ventral side of the 
neck. 
Operating procedure 
After shaving and placing the animal in supine po- 
sition on a heatpad aU-shaped ventral cervical incision 
was made. The trachea was exposed and cannulated 
and a tube was inserted (3 mm diameter) to facilitate 
spontaneous respiration of room air. The principles of 
experimental model have been published previously) 8,I9 
The present modification is described below. 
Approximately 25 mm of both the common jugular 
veins were carefully and completely dissected free 
of surrounding tissue using standard microsurgical 
instruments and an intravital microscope (Leica, Wild 
M651, Germany). Two caudal and one cranial 4-0 silk 
ligatures were placed around the vessels and loosely 
tied. Two non-traumatic vessel clamps (3V, S & T, 
Germany) were placed 10mm apart. The trapped 
blood inside the vessel was drained with a 0.4 mm 
cannula, and the segment was subsequently flushed 
with saline. The intima was destroyed with 1.0ml 
pilodocanol (5.0 mg/ml, Kreussler, Germany), which 
was slowly injected into the vessel segment for I min 
and incubated for an additional 4 min. The segment 
was again flushed with saline. One millilitre of the 
test substance was slowly injected into the vessel 
segment for I rain and incubated for another 9 min. 
The substance was incubated on an area which cor- 
responds to approximately 0.8 cm 2 (considering the 
vessel segment to be a geometrical cylinder, with the 
length of 10 mm and diameter of ~2.5 mm). Thereafter 
the vessel was flushed for the last time. During the 
9 min incubation one of the two caudal igatures was 
tied around the vessel and a 0.8 mm cannula, to cause 
a restricted blood flow. The vessel clamps were then 
removed and the thrombogenic area was exposed to 
the blood. With a standard microsurgical empty/refill 
test, 2° the patency was evaluated 30 and 120 min after 
removal of the vessel clamps. The vessel was gently 
occluded caudal to the traumatised area with a pair 
of microforceps and emptied further downstream with 
another pair of forceps. After the release of the first 
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pair of forceps the jugular vein refilling was assessed 8o 
and classified as patent (refilling) or occluded (no 70 
refilling). 
After 120 min the animals were killed with an over- "~ 6o 
dose of sodium pentobarbital. The remaining ligatures ~ 50 
were tied and the vessel segment was excised and "~ 
40 opened longitudinally and the (possible) thrombus 
was gently removed and weighed (wet weight). 
Plasma nalyses 
Whole blood was drawn (disregarding the first ml) 
from an indwelling catheter (diameter: 0.8mm) in 
the central ear artery into vials supplemented with 
0.13M sodium citrate and immediately centrifuged 
(4800 rpm, 5 rain). The platelet poor plasma was ali- 
quoted, frozen and stored at -80°C  until analysed. 
Blood was drawn as baseline, 3min after declamping 
and immediately before sacrifice. 
The clotting assays were performed on an ACL 300R 
clot timer (Instrumentation Laboratory, Italy) and were 
principally carried out using the APTT and PT (dilute- 
TF measurement) programs. For the APTT meas- 
urements ILS-ellagic acid reagent was used and for 
the PT measurements Innovin (Dade/Baxter, U.K.) 
reconstituted according to package insert and further 
diluted 1:500 with 25 mM CaCI2 immediately before the 
assay, providing greater sensitivity to TF dependent 
coagulation. Thus, TF was the rate limiting factor. 
Reference values were defined as mean + 2 S.D. 
The FVII protein level was assayed using a com- 
mercial enzyme-linked immunoassay (Dako, Den- 
mark). The assay detects human FVII, FVIIa and FFR- 
rFVIIa (FVII mass). The assay does not cross-react with 
rabbit FVII. 
Statistics 
The sample size was calculated to be large enough to 
minimize the risk of type II error. Non-parametric 
analyses were performed due to skew distribution. 
Thrombus weights were evaluated with Wilcoxon 
signed-rank test. The plasma parameters were firstly 
analysed with a variance analysis for paired data 
(Friedman's test). When appropriate, post hoc tests 
were performed with Wilcoxon signed-rank test. The 
patency was evaluated with Fisher's Exact test. p values 
<0.05 were considered significant. All calculations 
were performed on a Macintosh Power PC TM (Apple 
Computers ®, U.S.A.) using the StatView TM 4.5 software 
(Abacus ® , U.S.A.). 
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Fig. 1. Median thrombus weight (black line) and individual ob- 
servations, each pair (one animal) connected with a line. Statistical 
evaluation was performed with Wilcoxon signed rank test. 
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Fig. 2. Percent open vessels 30 and 120 min post-thrombus induction; 
statistical evaluation performed with Fisher's exact test. 
Results 
Thrombus weights and patency 
(Figures I and 2). One and a half milligrams FFR-rFVIIa 
significantly reduced the thrombus weight (p<0.001) 
from 25.0 mg (range: 2.4-80.9) to 2.3 mg (range: 0-18.7). 
The range of the thrombus weight was large; however, 
it was not larger than previously reported. 2°-24 Both 
the 30 and the 120 min patency tests were significantly 
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Table 1. For description of the clotting assays and the FVII protein assay see the section on materials and methods. 
The initial sample size was 20, one animal was omitted due to technical reasons. Two additional animals were 
omitted to the statistical analyses of the plasma parameters ince both could be considered to be outliers. They 
had an FVII protein concentration of >3.8 ~g/ml with a corresponding prolongation of the dilute-TF time to >95 s. 
Therefore, the final sample size, which the above is calculated, was 17. 
Dilute-TF time (sec) 
reference values: 39-57 
APTT (sec) 
reference values: 15-21 
FVII protein (ng/ml) 
Median Range Median Range Median Range 
Baseline 47 40-57 
3 min after declamping 42 36-52 
Sacrifice 41 3646 
18 16-20 <5 <5 
18 15-20 28 <5-300 
17 14-19 22 <5-70 
improved by FFR-rFVIIa (p<0.05 and p<0.001, re- 
spectively). Ninety-five per cent of the FFR-rFVIIa 
treated vessels were patent after 30 min, compared to 
63% of the vehicle treated vessels. At the 120min 
observation point the corresponding figures were 84 
and 26%. There was no statistical significant correlation 
between larger thrombi and occlusive thrombi (p = 
0.32). 
Plasma analyses 
(Table 1) APT-time and the dilute-TF time remained 
within the reference values throughout he entire 
study. FVII protein assay significantly increased at the 
second and third observation point (p<0.001, both) in 
comparison to the baseline value. 
Haemorrhagic evaluation 
Although the model was not designed specifically to 
evaluate bleeding, no bleeding tendency was observed 
during the experimental procedure. It was not possible 
during the surgical procedure to detect which one of  
the two vessels that were actively treated. Neither side 
had a greater or prolonged bleeding from the site of 
vessel wall puncture. 
Adverse vents 
No perioperative mortality occurred uring the study. 
Due to an accidental puncture of dorsal side of a vessel 
one animal did not receive the substance appropriately 
unilaterally and was therefore omitted in the analyses. 
Two additional animals were excluded from the 
plasma analyses ince they were clear outliers in com- 
parison of the rest of the 19 animals. These animals had 
an elevated FFR-rFVIIa protein concentration (>3.8 ~tg/ 
ml), which was paralleled with a prolonged -TF time 
(>95 s). No effect on the APT-time was seen. The other 
two endpoints (thrombus weight and patency) for 
these two outliers were no different from the rest of 
the study cohort. 
Discussion 
In the present study it was clearly shown that local 
application of an active-site inhibited recombinant 
FVIIa is capable of both reducing the thrombus weight 
and improving early patency in an injured vein model 
in the rabbit. This shows that the formation of thrombi 
in this model is TF dependent. It has previously been 
shown that exogenous recombinant TFPI reduces 
thrombus weight and improves patency in this 
model. 21-23 In the present modifications of the model 
we have used local delivery of the substance. Although 
our version may not be as sophisticated as local de- 
livery with microporous (Periflow TM, Cardiovascular 
Dynamics, Inc, U.S.A.) or coated (Hydroplus TM, Boston 
Scientific Corp, U.S.A.) angioplasty catheters, it was 
possible to demonstrate that topical application of 
FFR-rFVIIa was effective in preventing thrombus for- 
mation in a segment of injured vein without pro- 
longing the clotting time in the systemic blood (no 
prolongation of the APTT or dilute TF-time). 
Minute amounts of FVII protein were, however, 
detected in the plasma samples. The FVII protein 
most likely originated from isufficiently flushed vein 
segments; alternatively, but less likely, some FFR- 
rFVIIa was released from its binding sites on TF. 
It should, however, be emphasised that FFR-rFVIIa 
present in the peripheral blood did not prolong the 
dilute-TF clotting time, an assay specifically sensitive 
to the TF inhibition. 
Inhibition of the TF-dependent haemostatic mech- 
anism by using active-site inhibited rFVIIa has pre- 
viously been found to inhibit the thrombus formation 
Eur J Vasc Endovasc Surg Vol 15, June 1998 
Active-site Inhibited Human FVIla, Thrombosis and Patency 519 
in a baboon model 8-1° and in a rabbit model 11 as 
well as in cholesterol-fed rabbits. 12 Active-site inhibited 
rFVIIa also was found to decrease the restenosis 30 
days after mechanical vessel wall injury. 12'I3 In an ex 
vivo flow study of human blood inactivated FVIIa 
reduced TF induced thrombus deposition. 14 Fur- 
thermore, topical application of FFR-rFVIIa was cap- 
able of reducing thrombus formation and improving 
early patency in a micro-arterial thrombosis model in 
the rabbit, is To further evaluate the potential of local 
application of FFR-rFVIIa during interventional vas- 
cular procedures, further studies are in progress using 
FFR-rFVIIa soaked grafts. 
An ideal antithrombotic substance should be ef- 
ficient in preventing the formation of thrombosis with- 
out inducing clinically relevant bleeding. In the present 
venous thrombosis model no haemorrhage was ob- 
served during the experimental procedure. This is in 
accordance with experience in baboons, 9 in a cuticle 
bleeding model in the rabbit 25 and surgical bleeding 
in the rabbit. ~5 On the contrary, active-site inhibited 
rFVIIa (systematically administered) increased the 
bleeding volume and bleeding time in a rat gastric 
mucosa bleeding model. However, in that model low 
molecular weight (LMW) heparin in a dose used for 
major orthopaedic surgery gave the same bleeding 
as FFR-rFVIIa did. 26 Since patients undergoing major 
orthopaedic surgery and receiving the same dose of 
LMW heparin do not suffer clinically relevant bleed- 
ing, the specificity of the rat gastric mucosa bleeding 
model could be questioned. 
Although there is so far no significantly increased 
bleeding risk in the association with use of FFR-rFVIIa, 
it might be relevant to stress that rFVIIa (NovoSeven TM, 
Novo Nordisk, Denmark) for the treatment of bleed- 
ings reverses the FFR-rFVIIa induced coagulation in- 
hibition, l~ On the contrary no ideal antidote to LMW 
heparin, currently one of the most frequently used 
antithrombotic agents, exists since protamine, used to 
reverse standard heparin, does not fully do so with 
respect to LMW heparin. 27 In this context it also should 
be emphasised that standard and LMW heparin have 
shown sub-optimal antithrombotic effect in patients 
who have undergone balloon angioplasty and/or cor- 
onary thrombolysis. 28 Therefore, there is a need for 
more efficient thrombo-prophylaxis in this setting. 
Heparin and its derivatives thus are no optimal anti- 
coagulant in this setting, possibly due to the fact 
that thrombin bound to fibrin is not inhibited by the 
heparin-antithrombin complex. 29 On the other hand, 
with a specific inhibition of thrombin, including the 
fibrin-bound thrombin, bleeding is a clinical reality. 7
FFR-rFVIIa may offer a more attractive alternative. 
In conclusion, local application of recombinant act- 
ive-site inhibited human clotting factor VIIa (FFR- 
rFVIIa, 1.5 mg) significantly reduced thrombus weight 
and significantly improved patency in a rabbit venous 
thrombosis model without affecting a sensitive pro- 
thrombin time assay. 
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